BMS's Celgene subsidiary has lifted purchasing limits for 340B covered entities and non-340B buyers on its injectable acute myeloid leukemia (AML) drug Vidaza.
BMS Tells 340B Entities It Has Lifted Purchasing Limits on Leukemia Drug
Bristol Myers Squibb’s Celgene subsidiary has removed purchasing limits due to demand-related supply constraints on its injectable acute myeloid leukemia (AML) drug Vidaza that have been in place since May 2020.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
